Description
Summary Abstract
Aniracetam (1-(4-methoxybenzoyl)pyrrolidin-2-one; CAS 72432-10-1) is a synthetic pyrrolidinone compound and member of the racetam nootropic class. Its primary pharmacological mechanism is positive allosteric modulation (PAM) of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, the principal mediators of fast excitatory neurotransmission in the mammalian CNS. Aniracetam slows both the deactivation and desensitization of AMPA receptor ion channels by binding an allosteric site at the dimer interface of the ligand-binding domain, stabilizing the agonist-bound conformation. This prolongs glutamatergic synaptic currents and increases AMPA receptor-mediated ion flux. Aniracetam additionally modulates metabotropic glutamate receptors (mGluRs) and may facilitate cholinergic neurotransmission. Clinically approved in Japan (brand name Draganon/Sarpul) for treatment of behavioral and psychological symptoms of dementia following stroke and Alzheimer’s disease, aniracetam has demonstrated cognitive enhancement, anxiolytic, and anti-depressant-like properties across a range of preclinical and clinical paradigms.
Clinical Indications
Aniracetam’s AMPA receptor modulation supports investigation across several neurological and psychiatric research contexts:
- Cognitive Impairment in Dementia: Clinical trials in elderly patients with mild-to-moderate Alzheimer’s type dementia demonstrated aniracetam 1500 mg/day significantly outperformed placebo on cognitive tests at 4 and 6 months, and outperformed piracetam 2400 mg/day in 8 of 18 cognitive assessments in a 6-month comparative trial.
- Anxiety and Depression Research: Aniracetam’s dual modulation of AMPA receptors and mGluR2/3 produces anxiolytic and antidepressant-like effects in social interaction, elevated plus maze, and forced swim paradigms in rodents, supporting its use in research models of affective disorders.
- Opioid Tolerance and Dependence: AMPA receptor PAMs including aniracetam have demonstrated the ability to prevent and reverse acute morphine tolerance and dependence in murine models, identifying AMPAR modulation as a target for opioid-related research.
Contraindications
- Seizure-Sensitive Models: Positive AMPA receptor modulation increases excitatory synaptic gain; aniracetam and other AMPAR PAMs require caution in research models with seizure predisposition or compromised GABAergic inhibitory tone, as pro-convulsant effects have been observed at high concentrations.
- Short Plasma Half-Life Limitations: Aniracetam undergoes rapid hepatic hydrolysis to 4-methoxybenzoic acid and 2-pyrrolidinone (t½ ~1–2 hours), which complicates sustained receptor exposure protocols; dosing schedules in chronic studies must account for the rapid clearance profile.
- Impaired Cognitive Baseline Models: Published positive clinical outcomes are predominantly in subjects with pre-existing cognitive impairment; enhancement in cognitively intact subjects is less consistently demonstrated, which affects study design for enhancement versus restoration research questions.
Mechanism of Action (MOA)
Aniracetam modulates glutamatergic neurotransmission through two complementary mechanisms at ionotropic and metabotropic glutamate receptors:
AMPA Receptor Positive Allosteric Modulation
Aniracetam binds an allosteric site at the dimer interface of the AMPA receptor ligand-binding domain, between the S1 and S2 clamshell lobes. This stabilizes the LBD in the closed, agonist-bound conformation, slowing both receptor deactivation (rate of channel closure after glutamate unbinding) and desensitization (channel closure with glutamate still bound). The net effect is prolongation of excitatory postsynaptic currents and increased synaptic gain at glutamatergic synapses.
Metabotropic Glutamate Receptor Modulation
Aniracetam also acts as an allosteric modulator of mGluR2/3 (group II metabotropic glutamate receptors) and mGluR5. These receptors regulate presynaptic glutamate release and postsynaptic intracellular signaling cascades, and their modulation is thought to contribute to aniracetam’s anxiolytic and antidepressant-like properties distinct from its direct AMPAR potentiation.
Cholinergic Facilitation
Evidence suggests aniracetam facilitates cholinergic neurotransmission by enhancing high-affinity choline uptake and acetylcholine release. This is consistent with the clinical cognitive efficacy profile in Alzheimer’s disease models, where cholinergic deficits are a primary pathological feature, and may represent an additional mechanism beyond AMPAR potentiation for memory and attention enhancement.
Key Features & Specifications
Aniracetam is a well-characterized AMPAR PAM with clinical approval in Japan and an extensive preclinical and clinical evidence base:
Chemical Analysis
| Property | Specification Reference Data |
|---|---|
| IUPAC Name | 1-(4-methoxybenzoyl)pyrrolidin-2-one |
| CAS Number | 72432-10-1 |
| Molecular Formula | C12H13NO3 |
| Molecular Weight | 219.24 g/mol |
| PubChem CID | 2196 |
| Synonyms | Draganon, Sarpul, Ro 13-5057, CL 879 |
| Form / Variation | 400 MG Capsules (SKU C-000) |
Storage, Safety, and Handling
Storage Protocol
Store capsules at room temperature (15–25 °C) in a sealed, moisture-resistant container, protected from direct sunlight. Aniracetam is a fat-soluble compound; its absorption is enhanced by co-administration with fatty foods in clinical studies, a factor to account for in bioavailability-sensitive protocols. Shelf life is typically 2 years from manufacture under proper conditions.
Handling & Compliance
Standard laboratory PPE applies. Aniracetam is marketed as a prescription medication in Japan and several European countries, though it is not FDA-approved in the United States. The compound is not currently listed on the WADA prohibited list. Researchers conducting studies outside Japan should confirm local regulatory requirements governing pyrrolidinone nootropic compounds prior to obtaining or using aniracetam.